Total amount raised
$611.3 Millions
Latest funding date
Location
Insilico Medicine has made significant strides in the biotechnology sector, leveraging generative AI to transform drug discovery and development. The company's innovative approach has garnered attention and support from various investors.
Keep reading to explore the intricacies of Insilico Medicine's fundraising journey and the investors backing this pioneering platform.
What Is Insilico Medicine?
Insilico Medicine is a company specializing in AI-driven drug discovery and development. Their mission is to extend healthy productive longevity for everyone by transforming drug discovery and development with generative artificial intelligence.
Founded in 2014, Insilico Medicine operates from multiple global offices, including locations in Boston, New York, Montreal, Suzhou, Abu Dhabi, Shanghai, Taipei, and Hong Kong. The company leverages generative AI and robotics to create new AI-driven drug discovery pipelines, significantly reducing the time and cost to bring life-saving medications to patients.
Unfortunately, the specific names of the founders and the number of employees are not available from the provided sources.
How Much Funding Has Insilico Medicine Raised?
- Series A
- Amount Raised: $2.8M
- Date: February 2017
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To kickstart the company's AI-driven drug discovery initiatives.
- Series A
- Amount Raised: $4M
- Date: July 2017
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further develop AI platforms and expand research capabilities.
- Series A
- Amount Raised: $6M
- Date: June 2018
- Lead Investors: WuXi AppTec
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To enhance AI algorithms and support early-stage drug discovery projects.
- Series B
- Amount Raised: $37M
- Date: September 2019
- Lead Investors: Qiming Venture Partners
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To scale up operations and accelerate drug candidate development.
- Series C
- Amount Raised: $255M
- Date: June 2021
- Lead Investors: Warburg Pincus
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand AI capabilities and advance clinical trials for key drug candidates.
- Corporate Round
- Amount Raised: Not publicly disclosed
- Date: January 2022
- Lead Investors: Fosun Pharma
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To form strategic partnerships and enhance drug development pipelines.
- Series D
- Amount Raised: $60M
- Date: June 2022
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support late-stage drug development and regulatory approvals.
- Series D
- Amount Raised: $35M
- Date: August 2022
- Lead Investors: Prosperity7 Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To enhance AI platforms and expand the drug candidate portfolio.
- Debt Financing
- Amount Raised: $100M
- Date: December 2024
- Lead Investors: HSBC Hong Kong
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To secure working capital and support ongoing research projects.
- Series E
- Amount Raised: $110M
- Date: January 2025
- Lead Investors: Pudong Chuangtou, Value Partners
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To enhance AI platforms, upgrade laboratory infrastructure, and advance drug candidates.
Total Amount Raised: $609.8M. Current Valuation: Not publicly disclosed.
Key Investors
Unfortunately, the requested information about the major investors in Insilico Medicine and their details, investment focus areas, and notable investments was not found in the provided sources. The sources either did not contain relevant information or were example domains without specific data on Insilico Medicine's investors.
Here is a summary of the available information from the sources:
- Pudong Venture Capital
- Details: A Shanghai-based investment firm.
- Investment Focus Areas: Not explicitly mentioned.
- Notable Investments: Not available.
- Value Partners Group
- Details: An investment firm based in Hong Kong.
- Investment Focus Areas: Not explicitly mentioned.
- Notable Investments: Not available.
- Fosun Pharma
- Details: A major Chinese healthcare group.
- Investment Focus Areas: Pharmaceuticals, healthcare services, medical devices.
- Notable Investments: Not available.
- Warburg Pincus
- Details: A global private equity firm.
- Investment Focus Areas: Healthcare, technology, financial services.
- Notable Investments: Not available.
- Qiming Venture Partners
- Details: A leading Chinese venture capital firm.
- Investment Focus Areas: Technology, healthcare, consumer products.
- Notable Investments: Not available.
For more detailed information, accessing the actual Crunchbase page for Insilico Medicine after passing the verification process would be necessary.
What's Next for Insilico Medicine?
Insilico Medicine stands at the cusp of significant growth, driven by its recent $100 million Series E funding round. This capital infusion will enable the company to enhance its AI platforms, upgrade automated laboratory infrastructure, and advance its portfolio of drug candidates, including ISM001-055 for idiopathic pulmonary fibrosis (IPF). These advancements position Insilico Medicine to make substantial strides in the biotechnology sector.
With the successful Series E round, future fundraising opportunities appear promising. The involvement of major investors like Pudong Venture Capital and Value Partners Group suggests continued interest and potential for further investments. As Insilico Medicine progresses, it may attract additional funding to support its innovative drug discovery initiatives.
However, the path forward is not without challenges. Regulatory hurdles for new drug approvals, competition in the AI-powered drug discovery space, and technical complexities in enhancing AI platforms and laboratory infrastructure could pose significant obstacles. Navigating these challenges will be crucial for Insilico Medicine to realize its full potential and continue its pioneering work in AI-driven drug discovery.
Use Clay to Get Funding Data
Sales professionals, take your efforts to the next level by leveraging Clay’s platform to access comprehensive fundraising data on companies like Insilico Medicine and gather other critical business insights. Sign up for free and unlock the potential of data-driven sales strategies today.
